Faculty Opinions recommendation of A randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: treatment results through 1-year follow-up.

2010 ◽  
Author(s):  
Vladan Starcevic ◽  
Milan Latas
Keyword(s):  
Panic Disorder ◽  
Cognitive Behavioral Therapy ◽  
Randomized Trial ◽  
Selective Serotonin Reuptake Inhibitor ◽  
Reuptake Inhibitor ◽  
Serotonin Reuptake ◽  
Behavioral Therapy ◽  
Cognitive Behavioral ◽  
Treatment Results

scholarly journals Severe Hyperacusis, Photophobia, and Skin Hypersensitivity

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Alessandra Barbara Fioretti ◽  
Theodoros Varakliotis ◽  
Otello Poli ◽  
Manuela Cantagallo ◽  
Alberto Eibenstein
Keyword(s):  
Cognitive Behavioral Therapy ◽  
Selective Serotonin Reuptake Inhibitor ◽  
Medical Therapy ◽  
Reuptake Inhibitor ◽  
Serotonin Reuptake ◽  
Behavioral Therapy ◽  
Cognitive Behavioral ◽  
Selective Serotonin ◽  
Skin Hypersensitivity ◽  
Sound Therapy

We report a case of a patient with severe hyperacusis, photophobia, and skin hypersensitivity. The patient was initially treated with sound therapy and medical therapy for 4 months and successfully with a selective serotonin reuptake inhibitor (SSRI) and cognitive behavioral therapy which improved her mood and the tolerance for sounds and light.

Insight and Delusional Beliefs in Body Dysmorphic Disorder

2017 ◽  
Author(s):  
Katharine A. Phillips
Keyword(s):  
Cognitive Behavioral Therapy ◽  
Psychotic Disorder ◽  
Reuptake Inhibitor ◽  
Serotonin Reuptake ◽  
Body Dysmorphic Disorder ◽  
Behavioral Therapy ◽  
Cognitive Behavioral ◽  
Serotonin Reuptake Inhibitor

This chapter discusses insight (“delusionality”) in body dysmorphic disorder (BDD). BDD beliefs span a broad range of insight, from good to absent insight (i.e., delusional beliefs). About 70% of patients have poor or absent insight. Early emerging clues suggest possible neurobiologic bases of poorer insight in BDD. BDD’s delusional form (characterized by the absence of insight) appears to be the same disorder as its nondelusional form rather than a separate psychotic disorder. Consistent with this, serotonin-reuptake inhibitor (SRI) monotherapy is efficacious for delusional BDD as well as nondelusional BDD. Neuroleptic (antipsychotic) monotherapy is not currently recommended for delusional BDD. Cognitive-behavioral therapy (CBT) appears efficacious for both delusional and nondelusional BDD, but research is needed to determine whether a somewhat modified approach may be helpful for delusional beliefs. Insight often improves with SRIs and CBT.

scholarly journals Long-term stability of cognitive behavioral therapy effects for panic disorder with agoraphobia: A two-year follow-up study

2013 ◽  
Vol 51 (12) ◽  
pp. 830-839 ◽  
Author(s):  
Andrew T. Gloster ◽  
Christina Hauke ◽  
Michael Höfler ◽  
Franziska Einsle ◽  
Thomas Fydrich ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Cognitive Behavioral Therapy ◽  
Behavioral Therapy ◽  
Cognitive Behavioral ◽  
Term Stability ◽  
Long Term Stability ◽  
Follow Up Study

Treatment-Resistant Panic Disorder

CNS Spectrums ◽  
2004 ◽  
Vol 9 (10) ◽  
pp. 725-739 ◽  
Author(s):  
Borwin Bandelow ◽  
Eckart Rüther
Keyword(s):  
Panic Disorder ◽  
Cognitive Behavioral Therapy ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Rating Scale ◽  
Behavioral Therapy ◽  
Cognitive Behavioral ◽  
Selective Serotonin ◽  
Combination Treatments ◽  
Number Of Patients

AbstractA substantial number of patients with panic disorder and agoraphobia may remain symptomatic after standard treatment (including selective serotonin reuptake inhibitors, tricyclic antidepressants, benzodiazepines, or irreversible monamine oxidase inhibitors). In this review, recommendations for the treatment of patients with panic disorder and agoraphobia who do not respond to these drugs are provided. Nonresponse to drug treatment could be defined as a failure to achieve a 50% reduction on a standard rating scale after a minimum of 6 weeks of treatment in adequate dose. When initial treatments have failed, the medication should be changed to other standard treatments. In further attempts at treatment, drugs should be used that have shown promising results in preliminary studies, such as venlafaxine. Combination treatments may be used, such as the combination of an selective serotonin reuptake inhibitor and a benzodiazepine. Psychological treatments such as cognitive-behavioral therapy have to be considered in all patients, regardless whether they are nonresponders or not. According to existing studies, a combination of pharmacologic treatment with cognitive-behavioral therapy can be recommended.

scholarly journals RANDOMIZED TRIAL OF D-CYCLOSERINE ENHANCEMENT OF COGNITIVE-BEHAVIORAL THERAPY FOR PANIC DISORDER

2016 ◽  
Vol 33 (8) ◽  
pp. 737-745 ◽  
Author(s):  
Michael W Otto ◽  
Mark H Pollack ◽  
Sheila M Dowd ◽  
Stefan G Hofmann ◽  
Godfrey Pearlson ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Cognitive Behavioral Therapy ◽  
Randomized Trial ◽  
Behavioral Therapy ◽  
Cognitive Behavioral
Sign in / Sign up

Export Citation Format

Share Document